Neuragon
Neuragon offers AI-based CT biomarkers to help clinicians detect COPD and IPF early with objective progression insights. The technology analyzes CT imaging to derive biomarkers that inform clinical decisions and support trial design, targeting healthcare providers, researchers, and pharmaceutical partners in the medical imaging and respiratory space. It operates as a B2B healthcare solution focused on clinical decision support and early diagnosis, integrating with imaging workflows used by clinicians and trial teams. The approach leverages artificial intelligence to extract quantitative imaging features, enabling physicians to assess disease progression with data-driven reasoning. The market aims at scalable adoption in clinical settings and research programs to improve early intervention and trial outcomes.
Neuragon
Neuragon offers AI-based CT biomarkers to help clinicians detect COPD and IPF early with objective progression insights. The technology analyzes CT imaging to derive biomarkers that inform clinical decisions and support trial design, targeting healthcare providers, researchers, and pharmaceutical partners in the medical imaging and respiratory space. It operates as a B2B healthcare solution focused on clinical decision support and early diagnosis, integrating with imaging workflows used by clinicians and trial teams. The approach leverages artificial intelligence to extract quantitative imaging features, enabling physicians to assess disease progression with data-driven reasoning. The market aims at scalable adoption in clinical settings and research programs to improve early intervention and trial outcomes.